Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 426

Related Citations for PubMed (Select 7559897)

4.

Insulin-like growth factor-I and IGF binding protein-3 remain high after GnRH analogue therapy in girls with central precocious puberty.

Kanety H, Karasik A, Pariente C, Kauschansky A.

Clin Endocrinol (Oxf). 1996 Jul;45(1):7-12.

PMID:
8796132
5.

Use of combined Gn-RH agonist and hGH therapy for better attining the goals in precocious puberty treatment.

Tatò L, Saggese G, Cavallo L, Antoniazzi F, Corrias A, Pasquino AM, Cisternino M.

Horm Res. 1995;44 Suppl 3:49-54.

PMID:
8719441
6.
7.

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 in girls with premature thelarche.

Sales DS, Moreira AC, Camacho-Hübner C, Ricco RG, Daneluzzi JC, Campos AD, Martinelli CE Jr.

J Pediatr Endocrinol Metab. 2003 Jul-Aug;16(6):827-33.

PMID:
12948294
8.

Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.

Sklar CA, Rothenberg S, Blumberg D, Oberfield SE, Levine LS, David R.

J Clin Endocrinol Metab. 1991 Oct;73(4):734-8.

PMID:
1909701
9.

The acid-labile subunit of human ternary insulin-like growth factor-binding protein complex in girls with central precocious puberty before and during gonadotropin-releasing hormone analog therapy.

Cisternino M, Draghi M, Lauriola S, Scarcella D, Bernasconi S, Cavallo L, De Luca F, Lomeo A, Tatò L.

J Clin Endocrinol Metab. 2002 Oct;87(10):4629-33.

PMID:
12364447
10.

Two-year results of treatment with depot leuprolide acetate for central precocious puberty.

Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, Olney R, Wilson DM.

J Pediatr. 1992 Oct;121(4):634-40.

PMID:
1403402
11.

Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotropin-releasing hormone analog and cyproterone acetate.

Hertel NT, Stoltenberg M, Juul A, Main KM, Müller J, Nielsen CT, Lorenzen I, Skakkebaek NE.

J Clin Endocrinol Metab. 1993 Apr;76(4):924-7.

PMID:
8473407
12.

Serum inhibin A and inhibin B in central precocious puberty before and during treatment with GnRH agonists.

Sehested A, Andersson AM, Müller J, Skakkebaek NE.

Horm Res. 2000;54(2):84-91.

PMID:
11251372
14.

Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.

Boepple PA, Mansfield MJ, Wierman ME, Rudlin CR, Bode HH, Crigler JF Jr, Crawford JD, Crowley WF Jr.

Endocr Rev. 1986 Feb;7(1):24-33. Review.

PMID:
2937629
15.

Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.

Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, Francois R, Garandeau P, Lahlou N, Morel Y, et al.

J Clin Endocrinol Metab. 1986 Apr;62(4):670-7.

PMID:
2936759
16.

Suppression of sex steroids by a gonadotrophin-releasing hormone agonist increases serum growth hormone-binding protein activity in girls with central idiopathic precocious puberty.

Kobayashi Y, Murata A, Yasuda T, Minagawa M, Wataki K, Ohnishi H, Niimi H.

Clin Endocrinol (Oxf). 1994 Mar;40(3):351-5.

PMID:
8187298
19.

Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.

Suikkari AM, Tiitinen A, Stenman UH, Seppälä M, Laatikainen T.

Fertil Steril. 1991 May;55(5):895-9.

PMID:
1708731
20.

A study of anthropomorphic and biochemical characteristics in girls with central precocious puberty and thelarche variant.

Su PH, Wang SL, Chen JY, Chen SJ, Ke JC.

J Pediatr Endocrinol Metab. 2008 Mar;21(3):213-20.

PMID:
18540247
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk